Clinical Trial Update: A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection [Phase 2]

View source ↗

Summary

The Phase 2 trial of vapendavir for rhinovirus infection in hematopoietic stem cell transplant patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinovirus Infection
• Upper Respiratory Tract Infection

Drugs mentioned

• Vapendavir (vapendavir)

Snippet

Sponsor: Vaxart | Conditions: Rhinovirus, Upper Respiratory Tract Infection | Phase 2 | Status: WITHDRAWN